Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9

2.

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance).

Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA.

J Clin Oncol. 2016 Aug 1;34(22):2602-9. doi: 10.1200/JCO.2015.66.1595. Epub 2016 May 2.

PMID:
27138575
3.

Desiderata for Major Eligibility Criteria in Breast Cancer Clinical Trials.

Paulson ML, Weng C.

AMIA Annu Symp Proc. 2015 Nov 5;2015:2025-34. eCollection 2015.

4.

Bevacizumab and breast cancer: what does the future hold?

Stevenson CE, Nagahashi M, Ramachandran S, Yamada A, Bear HD, Takabe K.

Future Oncol. 2012 Apr;8(4):403-14. doi: 10.2217/fon.12.22. Review.

5.

Bevacizumab in metastatic breast cancer: when may it be used?

Goldfarb SB, Hudis C, Dickler MN.

Ther Adv Med Oncol. 2011 Mar;3(2):85-93. doi: 10.1177/1758834010397627.

6.

Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

Dirix LY, Van Dam PA, Prove AM, Vermeulen PB.

Ther Adv Med Oncol. 2010 Sep;2(5):331-42. doi: 10.1177/1758834010376301.

7.

Immunological Approaches in the Treatment of Metastasized Breast Cancer.

Müller V, Witzel I, Stickeler E.

Breast Care (Basel). 2009;4(6):359-366. Epub 2009 Dec 16.

8.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF.

Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035.

9.

Antiangiogenic therapies in early-stage breast cancer.

Derleth C, Mayer IA.

Clin Breast Cancer. 2010;10 Suppl 1:E23-31. doi: 10.3816/CBC.2010.s.004. Review.

Supplemental Content

Support Center